{"id":888365,"date":"2025-09-22T13:50:39","date_gmt":"2025-09-22T17:50:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/"},"modified":"2025-09-22T13:50:39","modified_gmt":"2025-09-22T17:50:39","slug":"celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/","title":{"rendered":"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress"},"content":{"rendered":"
\n

MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025. The presentation will provide detailed efficacy and safety data from the PIK3CA<\/em> wild-type cohort of the VIKTORIA-1 trial.<\/p>\n

Late Breaking Oral Presentation Details:<\/p>\n

\n Title<\/strong>:\u00a0Gedatolisib + fulvestrant \u00b1 palbociclib vs fulvestrant in patients with HR+\/HER2-\/PIK3CA<\/em> wild-type advanced breast cancer: First results from VIKTORIA-1<\/p>\n

\n Abstract Number<\/strong>: 3535<\/p>\n

\n Session Title<\/strong>: Proffered paper session 1: Breast Cancer, metastatic<\/p>\n

\n Date<\/strong>: October 18, 2025<\/p>\n

\n Time<\/strong>: 10:15 am \u2013 11:45 am CEST<\/p>\n

Late-breaking abstracts (LBA) accepted for a Proffered Paper Session at the ESMO Congress 2025 will be published online via the ESMO website on the day of presentation.<\/p>\n

\n About Celcuity<\/strong>\n <\/p>\n

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company’s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1\/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K\u03b1, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+\/HER2- advanced breast cancer (\u201cABC\u201d) has completed enrollment of and reported topline data for the PIK3CA<\/em> wild-type cohort, and is currently enrolling patients for the PIK3CA <\/em>mutant cohort. \u00a0A Phase 1\/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4\/6 inhibitor and fulvestrant as first-line treatment for patients with HR+\/HER2- ABC is currently enrolling patients. More detailed information about Celcuity\u2019s active clinical trials can be found at\u00a0ClinicalTrials.gov<\/a>. Celcuity is headquartered in Minneapolis.\u00a0Further information about Celcuity can be found at\u00a0www.celcuity.com<\/a>. Follow us on\u00a0LinkedIn<\/a>\u00a0and\u00a0X<\/a>.<\/p>\n

\n View source version of release on GlobeNewswire.com<\/a>\n <\/p>\n

\n Contacts:<\/strong>\u00a0<\/p>\n

Celcuity Inc.\u00a0
Brian Sullivan, bsullivan@celcuity.com<\/a>\u00a0
Vicky Hahne, vhahne@celcuity.com<\/a>\u00a0
(763) 392-0123\u00a0<\/p>\n

ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com<\/a>
(415) 513-1284<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025. The presentation will provide detailed efficacy and safety data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial. Late Breaking Oral Presentation Details: Title:\u00a0Gedatolisib + fulvestrant \u00b1 palbociclib vs fulvestrant in patients with HR+\/HER2-\/PIK3CA wild-type advanced breast cancer: First results from VIKTORIA-1 Abstract Number: 3535 Session Title: Proffered paper session 1: Breast Cancer, metastatic Date: October 18, 2025 Time: 10:15 … <\/p>\n

Continue reading “Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-888365","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCelcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025. The presentation will provide detailed efficacy and safety data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial. Late Breaking Oral Presentation Details: Title:\u00a0Gedatolisib + fulvestrant \u00b1 palbociclib vs fulvestrant in patients with HR+\/HER2-\/PIK3CA wild-type advanced breast cancer: First results from VIKTORIA-1 Abstract Number: 3535 Session Title: Proffered paper session 1: Breast Cancer, metastatic Date: October 18, 2025 Time: 10:15 … Continue reading "Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-22T17:50:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress\",\"datePublished\":\"2025-09-22T17:50:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/\"},\"wordCount\":394,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/\",\"name\":\"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=\",\"datePublished\":\"2025-09-22T17:50:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/","og_locale":"en_US","og_type":"article","og_title":"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - Market Newsdesk","og_description":"MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025. The presentation will provide detailed efficacy and safety data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial. Late Breaking Oral Presentation Details: Title:\u00a0Gedatolisib + fulvestrant \u00b1 palbociclib vs fulvestrant in patients with HR+\/HER2-\/PIK3CA wild-type advanced breast cancer: First results from VIKTORIA-1 Abstract Number: 3535 Session Title: Proffered paper session 1: Breast Cancer, metastatic Date: October 18, 2025 Time: 10:15 … Continue reading \"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-22T17:50:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress","datePublished":"2025-09-22T17:50:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/"},"wordCount":394,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/","name":"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=","datePublished":"2025-09-22T17:50:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMjkxNiM3MTU4MjEyIzIxNTcwMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=888365"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888365\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=888365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=888365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=888365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}